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Abstract
Aims/hypothesis Observational and mechanistic studies
have suggested a possible relationship between treatment
with metformin and decreased incidence of cancer in
participants with type 2 diabetes. We extracted data for
malignancies from the ADOPT (A Diabetes Outcome
Progression Trial) and RECORD (Rosiglitazone Evaluated
for Cardiovascular Outcomes and Regulation of Glycaemia
in Diabetes) randomised controlled clinical trials, in which
the efficacy and/or safety of metformin was assessed in
comparison with sulfonylureas and rosiglitazone.
Methods Neoplasm occurrences were collected as adverse
events in these studies. We reviewed and re-analysed the
individual participant data in both studies for serious
adverse events, malignancies reported as adverse events
and related neoplasms of special interest.
Results In ADOPT, 50 participants (3.4%) on metformin
and 55 (3.8%) on each of rosiglitazone and glibenclamide
(known as glyburide in the USA and Canada) developed
serious adverse event malignancies (excluding non-
melanoma skin cancers). This corresponds to 1.03, 1.12
and 1.31 per 100 person-years, giving hazard ratios for
metformin of 0.92 (95% CI 0.63–1.35) vs rosiglitazone and
0.78 (0.53–1.14) vs glibenclamide. In RECORD, on a
background of sulfonylurea, 69 (6.1%) participants devel-
oped malignant neoplasms in the metformin group, com-
pared with 56 (5.1%) in the rosiglitazone group (HR 1.22
[0.86–1.74]). On a background of metformin, 74 (6.7%)
participants in the sulfonylurea group developed malignant
neoplasms, compared with 57 (5.1%) in the rosiglitazone
group (HR 1.33 [0.94–1.88]).
Conclusions/interpretation The malignancy rates in these
two randomised controlled clinical trials do not support a
view that metformin offers any particular protection against
malignancy compared with rosiglitazone. However, they do
not refute the possibility of a difference compared with
sulfonylureas.
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Introduction
Observational analyses of data from population registries
that include people with diabetes have suggested an
association between use of metformin and decreased
prevalence of malignancy [1–3]. Knowledge of the
cellular biochemical effects of metformin suggests a
putative mechanism by which such an effect could be
mediated [4, 5]. Together the above notions have resulted
in metformin being endorsed as good news for people with
diabetes [6].
Observational studies are subject to various recognised
kinds of bias. Metformin may be a particular problem here,
as prescribers respond variably to concern in the elderly,
and in patients with renal, hepatic and cardiac disease,
targeting it to the obese but otherwise healthy individual
[7]. Mechanistic studies may also suffer attribution bias.
Randomised controlled clinical trials are generally believed
to offer a higher level of evidence, although they, too, are
not without problems. Here, we have taken the opportunity
offered by two large, long-term studies in people with
type 2 diabetes, in which metformin was randomised and
compared with other oral glucose-lowering agents, in
order to determine malignancy rates in participants on
these medications [8, 9].
Methods
All sponsored clinical trials are required to routinely report
serious adverse events to the manufacturer. The Interna-
tional Conference on Harmonisation of Technical Require-
ments for Registration of Pharmaceuticals for Human Use
recommends that cancers should be characterised as
‘medically important’ adverse events and therefore classi-
fied as serious adverse events [10], although some skin
cancers may only be reported as adverse events. Sponsor
manufacturers maintain comprehensive databases of serious
adverse events and malignancies, and routinely prepare
clinical trial reports with a major focus on adverse events
soon after completion of each study. For the current report,
the individual participant data of the following two studies
were accessed and examined: (1) A Diabetes Outcome
Progression Trial (ADOPT; ClinicalTrials.gov registration
no. NCT00279045); and (2) Rosiglitazone Evaluated for
Cardiovascular Outcomes and Regulation of Glycaemia in
Diabetes (RECORD; ClinicalTrials.gov registration no.
NCT00379769).
Manufacturer-sponsored studies, including ADOPT and
RECORD, are subject to site monitoring by external staff to
ensure study conduct. One activity of monitors is to ensure
local investigators identify and report serious adverse
events faithfully. However, some adverse events occur
remote from the study site and full medical details may not
be available. Where a term, such as ‘breast neoplasm’ is
ambiguous as to malignancy and no further information can
be obtained, it is counted as malignancy. In the summary
tables presented here, lower level terms referring to one
organ site (e.g. ‘colon cancer’, ‘colorectal carcinoma’,
‘malignant neoplasm of sigmoid colon’, ‘adenocarcinoma
of colon’) have been grouped together. Adverse events
were assessed for malignancies without reference to
treatment allocation.
Data are presented as participants with a malignancy
(reported as a serious adverse event, but excluding non-
melanoma skin cancers unless explicitly indicated otherwise),
per cent of those exposed and rate per 100 person-years.
Kaplan–Meier curves are presented to provide visual time-
dependent analysis. Hazard ratios and 95% CIs were
calculated by Cox proportional hazards regression for
metformin vs randomised comparators in the two studies
and for sulfonylureas vs rosiglitazone in the RECORD study.
Multivariate analysis to take account of crossover and other
drugusagewasnotrelevanttoADOPTandwasnotattempted
for the RECORD study because of the difficulties in
identifying likely bias arising from post-randomisation treat-
ment allocation [11].
Role of the study sponsor The sponsor of the studies
analysed (GlaxoSmithKline) archived the study data and
assisted in analysis of the data used in the present report.
Some further background data on the RECORD study was
supplied by sponsor statisticians. Otherwise, the paper was
prepared entirely by the authors, one of whom is an
employee of GlaxoSmithKline who is engaged in both
source studies, and one of whom is a company statistician
at GlaxoSmithKline.
Results
ADOPT clinical trial ADOPT was a monotherapy study of
efficacy of glucose-lowering with double-blind random-
isation to metformin, rosiglitazone and glibenclamide
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duration in the study was 4.0 years. Numbers treated were
very similar in the three groups, being 1,454, 1,456 and
1,441 respectively, with exposure of 4,906, 4,954 and 4,244
person-years respectively. Monotherapy failure occurred by
study end in 21% participants on metformin, 15% on
rosiglitazone and 34% on glibenclamide; participants were
not followed beyond this endpoint.
Malignancies reported as serious adverse events, but
excluding non-melanoma skin malignancies, occurred in 50
participants (3.4%) on metformin and in 55 (3.8%) on each
of rosiglitazone and glibenclamide. This corresponded to
1.03, 1.12 and 1.31 malignancies per 100 patient-years
(Table 1). The hazard ratio for metformin compared with
rosiglitazone was 0.92 (95% CI 0.63–1.35) and that for
metformin vs glibenclamide was 0.78 (95% CI 0.53–1.14)
(Table 1). Kaplan–Meier cumulative event curves are given
in Fig. 1.
RECORD clinical trial RECORD was a 5.5 year cardio-
vascular outcomes study of oral glucose-lowering combi-
nation therapy with rosiglitazone or metformin added to
sulfonylurea in one stratum, and rosiglitazone or sulfonyl-
urea added to metformin in the other stratum [9].
Accordingly, randomised comparisons can only be made
between metformin and rosiglitazone, and between sulfo-
nylurea and rosiglitazone within strata, but not between
metformin and sulfonylurea.
On background sulfonylurea, 1,122 people were
randomised to metformin and 1,103 to rosiglitazone.
Total study exposure was 6,126 and 6,110 person-years
respectively, with 82% of this time including exposure to
metformin and 87% to rosiglitazone, but only 9.5% and
5.4% respectively including exposure to insulin. As a
result of a rescue therapy algorithm, 27% of those in the
rosiglitazone group also had some exposure to metformin
later in the study.
Malignancies reported as serious adverse events, but
excluding non-melanoma skin malignancies, occurred in
69 (6.1%) participants in the metformin group, compared
with 56 (5.1%) participants in the rosiglitazone group,
giving a hazard ratio of 1.22 (95% CI 0.86–1.74)
(Table 2). Kaplan–Meier cumulative event curves are given
in Fig. 1. Per protocol (while on the randomised dual
therapy), 54 (4.8%) participants developed malignancy on
metformin and 43 (3.9%) on rosiglitazone (HR 1.12 [95%
CI 0.75–1.68]).
On background metformin, 1,105 people were rando-
mised to sulfonylurea and 1,117 to rosiglitazone. The
people in this stratum were notably more obese, but had
shorter duration of diabetes than those on background
sulfonylurea [9]. Total study exposure to sulfonylurea and
rosiglitazone was 6,146 and 6,228 person-years respective-
ly, with 84% of this time including exposure to sulfonylurea
and 88% exposure to rosiglitazone, but only 10% and 4%
of the time respectively including exposure to insulin. As a
result of a rescue therapy algorithm, 23% of those in the
rosiglitazone group also had some exposure to sulfonylurea
later in the study.
In the group randomised to sulfonylurea, 74 (6.7%)
participants developed malignant neoplasm, compared with
57 (5.1%) in the rosiglitazone group, hazard ratio 1.33
(95% CI 0.94–1.88). Kaplan–Meier cumulative event
curves are given in Fig. 1. Per protocol (while on the
Variable Metformin Rosiglitazone Glibenclamide
n 1,454 1,456 1,441
Study exposure (person-years) 4,906 4,954 4,244
Malignancies, n (%) 50 (3.4) 55 (3.8) 55 (3.8)
Rate (per 100-person-years)
a 1.03 1.12 1.31
HR (95% CI) vs rosiglitazone 0.92 (0.63–1.35)
HR (95% CI) vs glibenclamide 0.78 (0.53–1.14)
Table 1 Patient exposure and
malignancies in ADOPT
Data are based on number (n)o f
patients; malignancies are those
reported as serious adverse
events excluding non-melanoma
skin cancers
aAdjusted for study exposure
Variable Background sulfonylurea Background metformin
Metformin Rosiglitazone Sulfonylurea Rosiglitazone
n 1,122 1,103 1,105 1,117
Study exposure (person-years) 6,126 6,110 6,146 6,228
Malignancies, n (%) 69 (6.1) 56 (5.1) 74 (6.7) 57 (5.1)
Rate (per 100 person-years)
a 1.15 0.94 1.23 0.93
HR (95% CI) 1.22 (0.86–1.74) 1.33 (0.94–1.88)
Table 2 Patient exposure and
malignancies in RECORD
Data are based on number (n)o f
patients; malignancies are those
reported as serious adverse
events excluding non-melanoma
skin cancers
aAdjusted for study exposure
1840 Diabetologia (2010) 53:1838–1845randomised dual therapy), 60 (5.4%) participants developed
malignancies on sulfonylurea and 44 (3.9%) on rosiglita-
zone (HR 1.25 [95% CI 0.85–1.18]).
Single-organ category analyses In the ADOPT study the
number of malignancies reported in any one organ category
was low (Table 3). Some imbalance in non-melanoma skin
malignancies was noted. For men, prostate cancer rates did
not appear to differ between medications. For women,
breast, ovarian and uterine cancers showed no consistent
trends. No additional non-serious adverse event malignan-
cies (except non-melanoma skin) were identified.
Few malignancies inany one organ category were reported
in the RECORD study (Table 4). The only malignancy group
with a possible trend in favour of metformin was skin
cancers (three vs eight cases). Additionally, one case of
prostatic carcinoma in a participant allocated to rosiglitazone
was reported as a non-serious adverse event. Overall,
prostate cancer rates in men did not appear to differ between
medications. In women, breast, ovarian and uterine cancers
showed no consistent trends (Table 4).
Combined study/strata analysis No formal multiple treat-
ment comparison between strata in the RECORD study has
been performed, but on the assumption of equivalence for
rosiglitazone (Table 2), the relative risk for metformin vs
sulfonylurea would be 0.92. The ADOPT data comparing
metformin with rosiglitazone could be combined (meta-
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1,105 1,065 1,038 1,004 957 916 451
Rosiglitazone 1,117 1,079 1,052 1,020 983 953 463
Fig. 1 Kaplan–Meier event
curves for serious adverse event
malignancies in (a) ADOPT,
and (b) the metformin stratum
and (c) the sulfonylurea stratum
of RECORD. Hazard ratios are
given in Tables 1 and 2. Numb-
ers below panels, participants
(n) evaluable each year. Circles,
metformin; squares, rosiglita-
zone; diamonds, sulfonylurea
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sulfonylurea stratum. However, ethnic and geographical
origin, as well as background therapy differed between the
studies. A formal meta-analysis was therefore not performed.
Nevertheless, upon combination of the numbers of malignan-
cies in the two studies, the lower 95% CI would exclude a
greater than 17% (HR 1.07 [95% CI 0.83–1.39]) advantage of
metformin over rosiglitazone.
Discussion
Based on the analysis of these two randomised controlled
trials, metformin is not associated with any demonstrable
advantage over rosiglitazone and sulfonylureas in terms of
cancer rates, despite total study exposure of nearly 39,000
person-years and study durations of 4 to 6 years. Never-
theless, although the central estimates for hazard ratio of
cancer risk for metformin vs rosiglitazone were close to 1.0
in both studies (one higher, the other lower), the data for
sulfonylureas are less secure. Thus in ADOPT, the hazard for
metformin vs sulfonylureas was −22%, while in RECORD
the hazard for rosiglitazone vs sulfonylureas was −25%
(neither statistically significant). As others have suggested
from observational studies that metformin and sulfonylureas
might differ in terms of cancer risk [1, 3], our data can be
interpreted as being consistent with that hypothesis, with
rosiglitazone being as protective as metformin. It is
noteworthy that the study populations are fairly typical of
people with type 2 diabetes of moderate duration from
diagnosis, approaching a mean age of 60 years at baseline
and having mean BMI at entry of around 30 to 33 kg/m
2.
Obesity is one of the clearer associations seen with the
increased malignancy rate in the diabetes population [12].
The cancer rate of 1.07 patients per 100 person-years in the
two studies is consistent with UK national statistics for this
Variable Metformin Rosiglitazone Glibenclamide
n 1,454 1,456 1,441
Study exposure (person-years) 4,906 4,954 4,244
Malignancies
All 56 (3.9) 60 (4.1) 64 (4.4)
All non-skin 50 (3.4) 55 (3.8) 55 (3.8)
Breast 6 (1.0) 6 (0.9) 3 (0.5)
Endocrine 0 0 2 (0.1)
Colorectal 7 (0.5) 4 (0.3) 10 (0.7)
Gastric 1 (0.1) 1 (0.1) 1 (0.1)
Hepato-biliary 0 3 (0.2) 1 (0.1)
Intestinal 1 (0.1) 1 (0.1) 0
Oral and oesophagus 2 (0.1) 3 (0.2) 3 (0.2)
Pancreatic 0 5 (0.3) 0
Haematological 3 (0.2) 4 (0.3) 4 (0.3)
Metastases unknown 0 2 (0.1) 2 (0.1)
Unspecified 2 (0.1) 3 (0.2) 1 (0.1)
Nervous system 2 (0.1) 0 0
Bladder 4 (0.3) 2 (0.1) 4 (0.3)
Renal 1 (0.1) 2 (0.1) 2 (0.1)
Cervix/uterine 1 (0.2) 1 (0.2) 3 (0.5)
Ovarian 0 3 (0.5) 0
Prostatic 10 (1.2) 10 (1.2) 9 (1.1)
Testicular 1 (0.1) 0 0
Lung 6 (0.4) 5 (0.3) 7 (0.5)
Nasal/laryngeal 1 (0.1) 0 2 (0.1)
Melanoma 2 (0.1) 2 (0.1) 2 (0.1)
Skin (non-melanoma) 7 (0.5) 5 (0.3) 11 (0.8)
Basal cell carcinoma 6 (0.4) 5 (0.3) 10 (0.7)
Other 1 (0.1) 0 1 (0.1)
Sarcomas 0 1 (0.1) 0
Table 3 Numbers of partici-
pants developing malignancies
in ADOPT
Data are number (n) of patients
(%) with a neoplasm reported as
a serious adverse event
Per cent values for prostate and
for breast, cervix/uterine and
ovarian cancer are based on
men only and women only
1842 Diabetologia (2010) 53:1838–1845period and age group, allowing that investigators tend not
to admit higher risk people to these studies [13].
Although the strength of these data lie in their origin
from randomised controlled trials, thus removing the risk of
allocation bias that is associated with other types of study,
some caution should be exercised when considering the
data at face value. For example, these studies were not set
up with the primary intention of collecting data on
malignancies and so these events were not formally
adjudicated. However, as part of the regulatory require-
ment, a fairly vigorous process for ascertainment of serious
adverse events was in place, including regular monitoring
of the investigator site. Moreover, even in a blinded study
like ADOPT (RECORD being open label), some decisions
on whether a neoplasm is malignant or not may have been
made open to randomisation drug group and by manufac-
turer employees, allowing the possibility of conscious or
unconscious bias.
Even in large trials such as those considered here, the
numbers of cancer events are not large (Tables 1, 2, 3, 4)
and differences in other aspects of study conduct can affect
interpretation of results. Our results, which come from two
independent sources, are fairly secure with regard to the
comparison of metformin with rosiglitazone, with central
estimates of comparative risk being close to unity and no hint
of advantage to metformin. Rosiglitazone, to a greater extent
than metformin, is an insulin sensitiser, so both medications
may offer common protection against increased malignancy in
theobese.Althoughthenumbersofcancereventsinmetformin
and sulfonylurea groups of ADOPT are seemingly similar
Variable Background sulfonylurea Background metformin
Metformin Rosiglitazone Sulfonylurea Rosiglitazone
n 1,122 1,103 1,105 1,117
Study exposure (person-years) 6,126 6,110 6,146 6,228
Neoplasms/cancer
All 81 (7.2) 70 (6.3) 89 (8.1) 73 (6.5)
Malignant neoplasms (non-skin) 69 (6.1) 56 (5.1) 74 (6.7) 57 (5.1)
Genitourinary 22 (2.0) 23 (2.1) 27 (2.4) 18 (1.6)
Prostate 10 (1.8) 5 (0.9) 11 (1.9) 10 (1.7)
Renal 1 (<0.1) 4 (0.4) 6 (0.5) 3 (0.3)
Uterine 7 (1.3) 7 (1.2) 5 (1.0) 1 (0.2)
Ovarian 1 (0.2) 3 (0.5) 3 (0.6) 2 (0.4)
Bladder 3 (0.3) 4 (0.4) 2 (0.2) 2 (0.2)
Gastrointestinal 24 (2.1) 12 (1.1) 21 (1.9) 17 (1.5)
Pancreatic 6 (0.5) 1 (<0.1) 7 (0.6) 1 (<0.1)
Gall bladder/biliary 3 (0.3) 0 1 (<0.1) 3 (0.3)
Gastric 1 (<0.1) 5 (0.5) 2 (0.2) 2 (0.2)
Liver 2 (0.2) 0 1 (<0.1) 1 (<0.1)
Breast 8 (1.4) 4 (0.7) 9 (1.7) 7 (1.4)
Melanoma 0 2 (0.2) 2 (0.2) 2 (0.2)
Skin (non-melanoma) 3 (0.3) 8 (0.7) 5 (0.5) 7 (0.6)
Metastases (unknown primary) 8 (0.7) 4 (0.4) 5 (0.5) 5 (0.4)
Lung 3 (0.3) 9 (0.8) 6 (0.5) 3 (0.3)
Haematological 2 (0.2) 2 (0.2) 3 (0.3) 4 (0.4)
Leukaemia 1 (<0.1) 2 (0.2) 0 2 (0.2)
Lymphoma 1 (<0.1) 0 1 (<0.1) 1 (<0.1)
Head and neck 2 (0.2) 1 (<0.1) 4 (0.4) 1 (<0.1)
Endocrine 3 (0.3) 1 (<0.1) 2 (0.2) 2 (0.2)
Neurological 0 2 (0.2) 2 (0.2) 1 (<0.1)
Other 2 (0.2) 0 1 (<0.1) 0
Benign neoplasms 12 (1.1) 10 (0.9) 12 (1.1) 10 (0.9)
Colon/rectal polyp 4 (0.4) 1 (<0.1) 1 (<0.1) 0
Lipoma 0 0 1 (<0.1) 0
Table 4 Numbers of partici-
pants developing malignancies
and selected non-malignant
neoplasms in RECORD
Data are number (n) of people
(%) with a neoplasm reported as
a serious adverse event
Per cent values for prostate and
for breast, cervix/uterine and
ovarian cancer are based on
men only and women only
Selected benign neoplasms of
interest are included
Diabetologia (2010) 53:1838–1845 1843(Table1), thefewerperson-yearsofexposuretoglibenclamide
in the sulfonylurea population, a result of the greater number
of participants reaching the adverse glucose control endpoint,
means that the central estimate for the hazard ratio of
malignancies for metformin compared with sulfonylurea is
0.78 (95% CI 0.53–1.14). This, combined with the observa-
tion that in RECORD metformin was similar to rosiglitazone
on a background of sulfonylurea, but that rosiglitazone was
numerically better than sulfonylureas in the other arm
(Table 2), leaves open the possibility that metformin and
rosiglitazone may have a small advantage over sulfonylureas.
In RECORD there was some crossover between
therapies and use of other therapies such as insulin, as
is inevitable in any longer term glucose-control study as
islet beta cell dysfunction progresses. The effect of this
will be to dilute differences between the studied
medications. Nevertheless this crossover only becomes
proportionately significant towards the end of the study;
as a result total safety exposure to the randomised
preparations remained high over the 5.5 years of study
(82–88% of total study exposure in the different arms).
Exposure to insulin was also limited as participants
needed to reach HbA1c criteria for rescue therapy. As a
result, insulin exposure in all groups was ≤10% of study
exposure. The per protocol analyses of randomised treat-
ments led to similar conclusions to those from the
intention-to-treat population.
It is tempting in RECORD to make comparisons
between the two treatment strata, particularly as the cancer
rates in participants on rosiglitazone were the same in both
populations. However, such comparisons may be unsafe, as
the background metformin stratum was clearly more obese
and possibly therefore at higher background risk of cancer,
although a little younger [9].
Finally our analysis is of two active comparator studies
and thus cannot exclude the possibility that all the
medications have an absolute advantage or disadvantage
for any outcome, either over no medication use or over
other therapies. In particular, the issue of comparison of
metformin with insulin therapy is not addressed in the
present paper, although such data might be available from
the UK Prospective Diabetes Study (UKPDS) [14]. In the
UKPDS, deaths from cancer were too few for any
conclusion to be reached about differences between
metformin and conservative management arms (RR 0.71
[95% CI 0.29–1.76]), while in the main study the cancer
death rate was identical in the therapy (sulfonylurea or
insulin) and conservative arms (RR 0.98 [95% CI 0.64–
1.52]) [14, 15].
We conclude that these studies contain no suggestion
that metformin has an advantage over rosiglitazone in terms
of protection against malignancy. However, as the numbers
of malignancies in the studies are limited, the possibility
that sulfonylureas may have a small disadvantage (∼<25%)
over the others cannot be excluded by these data. In
addition, these data are not useful by themselves with
regard to specific malignancies and do not address the
question of whether oral glucose-lowering agents as a
whole offer protection vs insulin therapy.
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